Troriluzole is an experimental medication that has been investigated as a potential treatment for Machado–Joseph disease (MJD),[1] obsessive–compulsive disorder (OCD),[2][3] and glioblastoma.

[4] It is a prodrug formulation of the medication riluzole.

[2][4] While riluzole is typically taken twice-daily and on an empty stomach, troriluzole may offer a potential once-daily dosing with or without food along with greater bioavailability.

[2][4] In 2024, researchers published a study in the Journal of Neurochemistry that reported troriluzole could reverse some early Alzheimer's disease brain changes in mice, reduce harmful glutamate levels, and improve memory and learning abilities.

[5][6]